Omrix Biopharmaceuticals Ltd.
Omrix Biopharmaceuticals Ltd., a prominent player in the biopharmaceutical industry, is headquartered in Israel (IL) and operates extensively in various global markets. Founded in 2000, the company has established itself as a leader in the development and manufacturing of innovative therapeutic solutions, particularly in the fields of immunology and oncology. Omrix is renowned for its unique core products, including advanced biologics and biosimilars, which are designed to address critical medical needs. The company’s commitment to quality and innovation has positioned it favourably within the competitive landscape, earning recognition for its contributions to patient care. With a focus on research and development, Omrix continues to achieve significant milestones, solidifying its reputation as a trusted name in biopharmaceuticals.
DitchCarbon Score
How does Omrix Biopharmaceuticals Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Omrix Biopharmaceuticals Ltd.'s score of 51 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Omrix Biopharmaceuticals Ltd.'s reported carbon emissions
Omrix Biopharmaceuticals Ltd., headquartered in Israel (IL), currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the biopharmaceutical industry is increasingly focusing on sustainability and reducing greenhouse gas emissions. Companies in this sector are often encouraged to adopt science-based targets and engage in initiatives aimed at minimising their environmental impact. As Omrix Biopharmaceuticals continues to operate within this context, it may consider establishing measurable climate commitments in the future to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Omrix Biopharmaceuticals Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
